BridgeBio has demonstrably improved its development of an novel solution for cardiac amyloidosis, employing the compound. Initial patient data reveals promising benefits for patients affected from the severe disease. https://biotech944461.qodsblog.com/42280123/bridgebio-progresses-amyloidosis-treatment-through-attruby